Aclaris Therapeutics, Inc. Revenue
Aclaris Therapeutics, Inc. (ACRS) reported Revenue of $1.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Aclaris Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.63M, a 8.33% decline year-over-year.
- Aclaris Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.00M, a 37.18% increase year-over-year.
- Aclaris Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $1.29M, a 85.94% decline year-over-year.
- Aclaris Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $3.30M, a 24.09% decline year-over-year.
- Aclaris Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $7.83M, a 58.19% decline from fiscal 2024.
- Aclaris Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $18.72M, a 40.09% decline from fiscal 2023.
- Aclaris Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $31.25M, a 5.03% increase from fiscal 2022.
- Aclaris Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $29.75M, a 340.05% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.63M 10-Q · filed 2026-08-06 | $3.63M 10-Q · filed 2026-08-06 | $4.92M derived: sum of 3 quarters · filed 2026-08-06 | $8.22M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-07 | $3.29M derived: sum of 2 quarters · filed 2026-05-07 | $6.59M derived: sum of 3 quarters · filed 2026-05-07 | $8.37M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.59M derived: sum of 2 quarters · filed 2026-02-26 | $6.37M derived: sum of 3 quarters · filed 2026-08-06 | $7.83M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $3.30M 10-Q · filed 2025-11-06 | $5.08M derived: sum of 2 quarters · filed 2026-08-06 | $6.53M 10-Q · filed 2025-11-06 | $15.74M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $1.78M 10-Q · filed 2026-08-06 | $3.23M 10-Q · filed 2026-08-06 | $12.44M derived: sum of 3 quarters · filed 2026-08-06 | $16.79M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $1.46M 10-Q · filed 2026-05-07 | $10.67M derived: sum of 2 quarters · filed 2026-05-07 | $15.01M derived: sum of 3 quarters · filed 2026-05-07 | $17.78M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.56M derived: sum of 2 quarters · filed 2026-02-26 | $16.32M derived: sum of 3 quarters · filed 2026-02-26 | $18.72M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $4.35M 10-Q · filed 2025-11-06 | $7.11M derived: sum of 2 quarters · filed 2025-11-06 | $9.51M 10-Q · filed 2025-11-06 | $27.08M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $2.77M 10-Q · filed 2025-08-07 | $5.16M 10-Q · filed 2025-08-07 | $22.73M derived: sum of 3 quarters · filed 2025-08-07 | $32.02M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $2.40M 10-Q · filed 2025-05-08 | $19.97M derived: sum of 2 quarters · filed 2025-05-08 | $29.25M derived: sum of 3 quarters · filed 2025-05-08 | $31.12M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $17.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $26.85M derived: sum of 2 quarters · filed 2025-02-27 | $28.72M derived: sum of 3 quarters · filed 2025-02-27 | $31.25M 10-K · filed 2025-02-27 | ||||
| 2023-09-30 | $9.28M 10-Q · filed 2024-11-06 | $11.15M derived: sum of 2 quarters · filed 2024-11-06 | $13.68M 10-Q · filed 2024-11-06 | $21.43M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | $1.87M 10-Q · filed 2024-08-07 | $4.40M 10-Q · filed 2024-08-07 | $12.15M derived: sum of 3 quarters · filed 2024-08-07 | $31.17M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $2.53M 10-Q · filed 2024-05-07 | $10.28M derived: sum of 2 quarters · filed 2024-05-07 | $29.30M derived: sum of 3 quarters · filed 2024-05-07 | $30.83M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $26.77M derived: sum of 2 quarters · filed 2024-02-27 | $28.30M derived: sum of 3 quarters · filed 2024-02-27 | $29.75M 10-K · filed 2024-02-27 | ||||
| 2022-09-30 | $19.02M 10-Q · filed 2023-11-06 | $20.55M derived: sum of 2 quarters · filed 2023-11-06 | $22.00M 10-Q · filed 2023-11-06 | $23.50M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $1.53M 10-Q · filed 2023-08-07 | $2.98M 10-Q · filed 2023-08-07 | $4.48M derived: sum of 3 quarters · filed 2024-02-27 | $6.14M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $1.45M 10-Q · filed 2023-05-08 | $2.95M derived: sum of 2 quarters · filed 2024-02-27 | $4.61M derived: sum of 3 quarters · filed 2024-02-27 | $6.44M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $3.16M derived: sum of 2 quarters · filed 2024-02-27 | $4.98M derived: sum of 3 quarters · filed 2024-02-27 | $6.76M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $1.66M 10-Q · filed 2022-11-08 | $3.48M derived: sum of 2 quarters · filed 2022-11-08 | $5.26M 10-Q · filed 2022-11-08 | $6.84M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $1.82M 10-Q · filed 2022-08-03 | $3.60M 10-Q · filed 2022-08-03 | $5.18M derived: sum of 3 quarters · filed 2023-02-23 | $6.63M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $1.78M 10-Q · filed 2022-05-10 | $3.36M derived: sum of 2 quarters · filed 2023-02-23 | $4.81M derived: sum of 3 quarters · filed 2023-02-23 | $6.85M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $3.03M derived: sum of 2 quarters · filed 2023-02-23 | $5.08M derived: sum of 3 quarters · filed 2023-02-23 | $6.48M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $1.45M 10-Q · filed 2021-11-02 | $3.50M derived: sum of 2 quarters · filed 2021-11-02 | $4.90M 10-Q · filed 2021-11-02 | $6.00M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-06-30 | $2.05M 10-Q · filed 2021-08-05 | $3.45M 10-Q · filed 2021-08-05 | $4.55M derived: sum of 3 quarters · filed 2022-02-24 | $5.53M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-03-31 | $1.41M 10-Q · filed 2021-05-07 | $2.50M derived: sum of 2 quarters · filed 2022-02-24 | $3.48M derived: sum of 3 quarters · filed 2022-02-24 | $4.37M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.08M derived: sum of 2 quarters · filed 2022-02-24 | $2.96M derived: sum of 3 quarters · filed 2022-02-24 | $4.23M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $983.00K 10-Q · filed 2020-11-04 | $1.87M derived: sum of 2 quarters · filed 2020-11-04 | $3.13M 10-Q · filed 2020-11-04 | $6.80M derived: sum of 4 quarters · filed 2020-11-04 | ||||
| 2019-06-30 | $886.00K 10-Q · filed 2020-08-07 | $5.87M 10-Q · filed 2019-08-08 | $2.15M 10-Q · filed 2020-08-07 | $10.91M 10-Q · filed 2019-08-08 | $5.82M derived: sum of 3 quarters · filed 2020-08-07 | $6.94M derived: sum of 4 quarters · filed 2020-08-07 | ||
| 2019-03-31 | $1.26M 10-Q · filed 2020-05-07 | $5.04M 10-Q · filed 2019-05-08 | $4.93M derived: sum of 2 quarters · filed 2020-05-07 | $6.05M derived: sum of 3 quarters · filed 2020-05-07 | $9.73M derived: sum of 4 quarters · filed 2020-05-07 | |||
| 2018-12-31 | $3.67M 10-K · filed 2019-03-18 | $4.79M derived: sum of 2 quarters · filed 2019-11-07 | $8.46M derived: sum of 3 quarters · filed 2019-11-07 | $6.15M 10-K · filed 2021-02-25 | $10.09M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $1.12M 10-Q · filed 2019-11-07 | $1.63M 10-Q · filed 2018-11-06 | $4.79M derived: sum of 2 quarters · filed 2019-11-07 | $4.38M 10-Q · filed 2019-11-07 | $6.42M 10-Q · filed 2018-11-06 | $6.91M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $3.68M 10-Q · filed 2019-08-08 | $4.79M 10-Q · filed 2019-08-08 | $5.79M derived: sum of 3 quarters · filed 2019-08-08 | $6.48M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $1.12M 10-Q · filed 2019-05-08 | $2.12M derived: sum of 2 quarters · filed 2019-05-08 | $2.80M derived: sum of 3 quarters · filed 2019-05-08 | |||||
| 2017-12-31 | $999.00K 10-K · filed 2019-03-18 | $1.68M derived: sum of 2 quarters · filed 2019-03-18 | $1.68M 10-K · filed 2020-02-25 | |||||
| 2017-09-30 | $684.00K 10-K · filed 2019-03-18 | $684.00K 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |